Skip to main content

Toyobo Gene Analysis to Evaluate Crucell's Cell Generation Tech

NEW YORK (GenomeWeb News) – Dutch biotech company Crucell said today that Toyobo Gene Analysis will evaluate Crucell’s cell line technology for use in producing recombinant proteins for third-party customers.
 
Toyobo Gene Analysis is a wholly-owned subsidiary of Osaka, Japan-based Toyobo.
 
Crucell’s Star Technology contains elements that “enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells,” the company said. Crucell believes this technology could be used to increase production yields of recombinant proteins, which could lower the cost of producing them.
 
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.